10th Feb 2023 14:15
Celadon Pharmaceuticals Plc
("Celadon" or the "Company")
Notification of transactions by persons discharging managerial responsibility
London, 10 February 2023 - Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the research, cultivation, manufacturing and sale of breakthrough cannabis-based medicines, announces that an award of options to acquire the Company's shares for their nominal value of £0.01 was granted to an Executive Director on 9 February 2023 under the Company's Long Term Incentive Plan ("LTIP") as shown below. The Options will vest on the third anniversary of grant on 9 February 2026, subject to the achievement of performance criteria. Once vested, the awards must be held for two years.
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Jonathan Turner | ||||
2 | Reason for the notification | |||||
a) | Position / status | PDMR - Chief Financial Officer | ||||
b) | Initial notification / Amendment | Initial Notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Celadon Pharmaceuticals plc | ||||
b) | LEI | 213800YXCATORT475807 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of £0.01 GB00BDQYGP38 | ||||
b) | Nature of the transaction | Award over nominal cost options under the Celadon Pharmaceuticals plc Long Term Incentive Plan | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Price | N/A Single Transaction | ||||
e) | Date of the transaction | 9 February 2023 | ||||
f) | Place of the transaction | London | ||||
Enquiries:
Celadon Pharmaceuticals Plc |
|
James Short Jonathan Turner Arthur Wakeley | Via Powerscourt |
|
|
Canaccord Genuity Limited (Nominated Adviser and Broker) |
|
Bobbie Hilliam / Andrew Potts / Patrick Dolaghan | +44 (0)20 7523 8000 |
Powerscourt Group | |
Sarah MacLeod / Nick Johnson / Sam Austrums / Ibrahim Khalil | +44 (0)20 7250 1446
|
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility operates to an EU-GMP standard and comprises indoor hydroponic cultivation, proprietary GMP extraction and manufacturing and an analytical and R&D laboratory. The Company's subsidiary, LVL, owns a MHRA conditionally-approved clinical trial using cannabis based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics which is developing a licenced cannabinoid medicine to treat children with Autism Spectrum Disorder.
For further information please visit our website www.celadonpharma.com
Related Shares:
Celadon Pharmaceuticals